Company Overview and News

Global and China Automotive Steering System Industry Report 2017 - Research and Markets

2017-06-19 prnewswire
Research and Markets has announced the addition of the "Global and China Automotive Steering System Industry Report, 2017-2021" report to their offering.

China Automotive Systems Buyout Price Should Be Raised To At Least $7.50

2017-06-13 seekingalpha
China Automotive Systems, a major supplier of steering gear to the Chinese auto industry, received a buyout offer of $5.45/share from Chairman Hanlin Chen.

What analysts say to buy as Shenzhen-Hong Kong stock link opens

2016-12-04 themalaymailonline
A businessman walks with an umbrella in the financial area of Pudong in Shanghai, May 30, 2013. — Reuters picHONG KONG, Dec 5 — After months of anticipation, the opening day of Shenzhen’s exchange link with Hong Kong has finally arrived.

Fifth day of Hong Kong rises, as Britain votes and traders anticipate Stock Connect test run

2016-06-23 scmp
Hong Kong’s stock market extended its gain to five days in a row on Thursday, as confidence remained high that Britain would vote to remain a member of the European Union and speculation grew over the launch of Shenzhen-Hong Kong Stock Connect scheme.

Hong Kong stocks close higher, betting on UK staying in EU, while mainland stocks lower

2016-06-23 scmp
Gains fuelled by growing expectations that Britain will vote to remain a member of the EU and on renewed speculation over the launch of Shenzhen Hong Kong Stock Connect

China stocks near 2-week high as test run revealed for trading link

2016-06-22 scmp
Stocks in China and Hong Kong both closed at their highest levels in nearly two weeks on Wednesday, after news of a system test run by Hong Kong stock exchange reignited hopes of a launch soon of the much-anticipated stock trading link between Shenzhen and Hong Kong.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...